Latest & greatest articles for corticosteroids

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on corticosteroids or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on corticosteroids and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for corticosteroids

82. Stress-Dose Corticosteroid Versus Placebo in Neonatal Cardiac Operations: A Randomized Controlled Trial

Stress-Dose Corticosteroid Versus Placebo in Neonatal Cardiac Operations: A Randomized Controlled Trial 28434547 2017 04 24 2017 04 24 1552-6259 2017 Apr 20 The Annals of thoracic surgery Ann. Thorac. Surg. Stress-Dose Corticosteroid Versus Placebo in Neonatal Cardiac Operations: A Randomized Controlled Trial. S0003-4975(17)30248-5 10.1016/j.athoracsur.2017.01.111 Corticosteroids can improve the hemodynamic status of neonates with postoperative low cardiac output syndrome after cardiac (...) operations. This study compared a prophylactically administered stress-dose corticosteroid (SDC) regimen against placebo on inflammation, adrenocortical function, and hemodynamic outcome. Forty neonates undergoing elective open heart operations were randomized into two groups. The SDC group received perioperatively 2 mg/kg methylprednisolone, and 6 hours after the operation, a hydrocortisone infusion (0.2 mg/kg/h) was started with tapering doses for 5 days. Placebo was administered in a similar fashion

EvidenceUpdates2017

83. Acute paraparesis and sensory loss following intravenous corticosteroid administration in a case of longitudinally extensive transverse myelitis caused by spinal dural arteriovenous fistula: case report and review of literature

Acute paraparesis and sensory loss following intravenous corticosteroid administration in a case of longitudinally extensive transverse myelitis caused by spinal dural arteriovenous fistula: case report and review of literature 28546874 2018 11 13 2058-6124 3 2017 Spinal cord series and cases Spinal Cord Ser Cases Acute paraparesis and sensory loss following intravenous corticosteroid administration in a case of longitudinally extensive transverse myelitis caused by spinal dural arteriovenous

Spinal cord series and cases2017 Full Text: Link to full Text with Trip Pro

84. Overcoming barriers to intranasal corticosteroid use in patients with uncontrolled allergic rhinitis

Overcoming barriers to intranasal corticosteroid use in patients with uncontrolled allergic rhinitis 29354557 2018 11 13 2230-5254 6 2017 Integrated pharmacy research & practice Integr Pharm Res Pract Overcoming barriers to intranasal corticosteroid use in patients with uncontrolled allergic rhinitis. 109-119 10.2147/IPRP.S129544 Patients suffering from allergic rhinitis often attempt to self-manage their symptoms and may seek advice from pharmacists about nonprescription product choices (...) . Several drug classes, both prescription and over-the-counter (OTC), are available, including intranasal corticosteroids (INCSs); oral, intranasal, and ocular antihistamines; leukotriene antagonists; and topical and systemic decongestants, as well as immunotherapies. Selection of the optimal treatment approach depends on the temporal pattern, frequency, and severity of symptoms as well as the patient's age. Nasal congestion is typically the most bothersome symptom, although rhinorrhea, postnasal drip

Integrated pharmacy research & practice2017 Full Text: Link to full Text with Trip Pro

85. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. BACKGROUND: Dupilumab (an anti-interleukin-4-receptor-α monoclonal antibody) blocks signalling of interleukin 4 and interleukin 13, type 2/Th2 cytokines implicated in numerous allergic diseases ranging from asthma to atopic dermatitis. Previous 16-week monotherapy studies showed (...) that dupilumab substantially improved signs and symptoms of moderate-to-severe atopic dermatitis with acceptable safety, validating the crucial role of interleukin 4 and interleukin 13 in atopic dermatitis pathogenesis. We aimed to evaluate the long-term efficacy and safety of dupilumab with medium-potency topical corticosteroids versus placebo with topical corticosteroids in adults with moderate-to-severe atopic dermatitis. METHODS: In this 1-year, randomised, double-blinded, placebo-controlled, phase 3

Lancet2017

86. Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk

Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk 28416587 2017 04 18 2017 04 18 1468-201X 2017 Apr 17 Heart (British Cardiac Society) Heart Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk. heartjnl-2016-310897 10.1136/heartjnl-2016-310897 Cardiovascular disease (CVD) and chronic obstructive pulmonary disease (COPD) often coexist. We assessed the effect (...) attack (TIA)) by Cox regression and by clinician-reported CVD adverse events across the four groups: once-daily inhaled placebo (n=4111), long-acting beta2-agonist (vilanterol (VI) 25 µg; n=4118), corticosteroid (fluticasone furoate (FF) 100 µg; n=4135) and combination therapy (FF/VI; n=4121). Participants were predominantly middle-aged (mean 65 (SD 8) years) men (75%) with overt CVD (66%). The composite CVD endpoint occurred in 688 patients (first event: sudden death (35%), acute coronary syndrome

EvidenceUpdates2017 Full Text: Link to full Text with Trip Pro

87. Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study.

Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. Objective To determine the frequency of prescriptions for short term use of oral corticosteroids, and adverse events (sepsis, venous thromboembolism, fractures) associated with their use. Design Retrospective cohort study and self controlled case series. Setting Nationwide dataset of private insurance claims. Participants Adults aged 18 to 64 years who were continuously (...) enrolled from 2012 to 2014. Main outcome measures Rates of short term use of oral corticosteroids defined as less than 30 days duration. Incidence rates of adverse events in corticosteroid users and non-users. Incidence rate ratios for adverse events within 30 day and 31-90 day risk periods after drug initiation. Results Of 1 548 945 adults, 327 452 (21.1%) received at least one outpatient prescription for short term use of oral corticosteroids over the three year period. Use was more frequent among

BMJ2017

88. Role of caesarean and antenatal corticosteroids in very low birth weight infants

Role of caesarean and antenatal corticosteroids in very low birth weight infants Evidencias en pediatría - Role of caesarean and antenatal corticosteroids in very low birth weight infants Searching, please wait Show menu Library Management You did not add any article to your library yet. | Search Evidence-Based decision making Evidence-Based decision making Show menu Library Management You did not add any article to your library yet. × User Password Log in × Reset password If you need to reset (...) your password please enter your email and click the Send button. You will receive an email to complete the process. Email Send × Library Management × March 2017. Volume 13. Number 1 Role of caesarean and antenatal corticosteroids in very low birth weight infants Rating: 0 (0 Votes) Reviewers: , . | Newsletter Free Subscription Regularly recieve most recent articles by e-mail Subscribe × Newsletter subscription: Email Confirm email I accept the journal’s privacy policy. Subscribe × Warnings

Evidencias en Pediatría2017

89. Exposure to any antenatal corticosteroids and outcomes in preterm infants by gestational age: prospective cohort study.

Exposure to any antenatal corticosteroids and outcomes in preterm infants by gestational age: prospective cohort study. Objective To determine whether exposure to any antenatal corticosteroids is associated with a lower rate of death at each gestational age at which administration is currently recommended. Design Prospective cohort study. Settings 300 participating neonatal intensive care units of the Pediatrix Medical Group in the United States. Participants 117 941 infants 23 0/7 to 34 6/7 (...) weeks' gestational age born between 1 January 2009 and 31 December 2013. Exposure Any antenatal corticosteroids. Main outcomes measures Death or major hospital morbidities analyzed by gestational age and exposure to antenatal corticosteroids with models adjusted for birth weight, sex, mode of delivery, and multiple births. Results Infants exposed to antenatal corticosteroids (n=81 832) had a significantly lower rate of death before discharge at each gestation 29 weeks or less, 31 weeks, and 33-34

BMJ2017 Full Text: Link to full Text with Trip Pro

90. Differential Effects of Estrogen on Corticosteroid-Binding Globulin Forms Suggests Reduced Cleavage in Pregnancy

Differential Effects of Estrogen on Corticosteroid-Binding Globulin Forms Suggests Reduced Cleavage in Pregnancy 29264477 2018 11 13 2472-1972 1 3 2017 Mar 01 Journal of the Endocrine Society J Endocr Soc Differential Effects of Estrogen on Corticosteroid-Binding Globulin Forms Suggests Reduced Cleavage in Pregnancy. 202-210 10.1210/js.2016-1094 Corticosteroid-binding globulin (CBG) is secreted as high-affinity CBG (haCBG), which may be cleaved by tissue proteases to low-affinity CBG (laCBG

Journal of the Endocrine Society2017 Full Text: Link to full Text with Trip Pro

91. Two-Year Follow-up Study of Membranous Nephropathy Treated With Tacrolimus and Corticosteroids Versus Cyclical Corticosteroids and Cyclophosphamide

Two-Year Follow-up Study of Membranous Nephropathy Treated With Tacrolimus and Corticosteroids Versus Cyclical Corticosteroids and Cyclophosphamide 29142979 2018 11 13 2468-0249 2 4 2017 Jul Kidney international reports Kidney Int Rep Two-Year Follow-up Study of Membranous Nephropathy Treated With Tacrolimus and Corticosteroids Versus Cyclical Corticosteroids and Cyclophosphamide. 610-616 10.1016/j.ekir.2017.02.004 Both cCTX/GCs and CNIs are recommended as first-line agents in the management (...) of PMN. The present study is an extended report of patients randomized to receive TAC/GCs or cCTX/GCs at 2 years post randomization. Seventy patients enrolled in the clinical trial Tacrolimus Combined With Corticosteroids Versus Modified Ponticelli Regimen in Treatment of Idiopathic Membranous Nephropathy: Randomized Control Trial were followed quarterly between 12 and 24 months. At the end of 24 months, 3 patients were lost to follow-up. At 18 months, 66% and 89% ( P = 0.04) were in remission in TAC

Kidney international reports2017 Full Text: Link to full Text with Trip Pro

92. Severe Adverse Effects Associated With Corticosteroid Treatment in Patients With IgA Nephropathy

Severe Adverse Effects Associated With Corticosteroid Treatment in Patients With IgA Nephropathy 29142978 2018 11 13 2468-0249 2 4 2017 Jul Kidney international reports Kidney Int Rep Severe Adverse Effects Associated With Corticosteroid Treatment in Patients With IgA Nephropathy. 603-609 10.1016/j.ekir.2017.02.003 Few data are available on the risk of SAEs in corticosteroid users in IgAN populations. We describe the prevalence and risk factors of corticosteroid-related SAEs in a Chinese cohort (...) . A total of 1034 IgAN patients were followed up in our renal center from 2003 to 2014. Prevalence of corticosteroid use and corticosteroid-related SAEs were noted. Logistic regression was used to search for risk factors of SAEs in corticosteroid users. Of the 369 patients with steroids therapy, 46 patients (12.5%) with 58 events suffered SAEs, whereas only 18 patients (2.7%) without corticosteroids suffered SAEs (OR: 5.45; 95% CI: 3.07-9.68; P < 0.001). SAEs included diabetes mellitus ( n = 19, 5.1

Kidney international reports2017 Full Text: Link to full Text with Trip Pro

93. Intra-articular corticosteroids versus intra-articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicentre, prospective, randomised, open-label trial.

Intra-articular corticosteroids versus intra-articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicentre, prospective, randomised, open-label trial. BACKGROUND: Little evidence-based information is available to guide the treatment of oligoarticular juvenile idiopathic arthritis. We aimed to investigate whether oral methotrexate increases the efficacy of intra-articular corticosteroid therapy. METHODS: We did this prospective, open-label, randomised (...) trial at ten hospitals in Italy. Using a concealed computer-generated list, children younger than 18 years with oligoarticular-onset disease were randomly assigned (1:1) to intra-articular corticosteroids alone or in combination with oral methotrexate (15 mg/m 2 ; maximum 20 mg). Corticosteroids used were triamcinolone hexacetonide (shoulder, elbow, wrist, knee, and tibiotalar joints) or methylprednisolone acetate (ie, subtalar and tarsal joints). We did not mask patients or investigators

Lancet2017 Full Text: Link to full Text with Trip Pro

94. Sacroiliac joint injections with corticosteroids for treatment of chronic low back pain

Sacroiliac joint injections with corticosteroids for treatment of chronic low back pain Sacroiliac joint injections with corticosteroids for treatment of chronic low back pain Sacroiliac joint injections with corticosteroids for treatment of chronic low back pain HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Sacroiliac joint injections (...) with corticosteroids for treatment of chronic low back pain. Lansdale: HAYES, Inc. Healthcare Technology Brief Publication. 2016 Authors' objectives The sacroiliac joint (SIJ) has been implicated as the primary source of pain in 10% to 30% of patients with chronic low back pain. Description of Technology: This health technology assessment focuses on therapeutic injections of corticosteroid and local anesthetic into the SIJ to treat SIJ pain that is refractory to noninvasive therapies. These injections are usually

Health Technology Assessment (HTA) Database.2017

95. Corticosteroids as adjuvant therapy for ocular toxoplasmosis.

Corticosteroids as adjuvant therapy for ocular toxoplasmosis. BACKGROUND: Ocular infection caused by Toxoplasma gondii, a parasite, may result in inflammation in the retina, choroid, and uvea, and consequently lead to complications such as glaucoma, cataract, and posterior synechiae. OBJECTIVES: The objective of this systematic review was to assess the effects of adjunctive use of corticosteroids to anti-parasitic therapy versus anti-parasitic therapy alone for ocular toxoplasmosis. SEARCH (...) compared anti-parasitic therapy plus corticosteroids versus anti-parasitic therapy alone, different doses or times of initiation of corticosteroids. DATA COLLECTION AND ANALYSIS: Two authors independently screened titles and abstracts retrieved through the electronic searches. We retrieved full-text reports of studies categorized as 'unsure' or 'include' after we reviewed the abstracts. Two authors independently reviewed each full-text report for eligibility. Discrepancies were resolved through

Cochrane2017 Full Text: Link to full Text with Trip Pro

96. Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy.

Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy. BACKGROUND: Corticosteroid treatment is considered the 'gold standard' for Duchenne muscular dystrophy (DMD); however, it is also known to induce osteoporosis and thus increase the risk of vertebral fragility fractures. Good practice in the care of those with DMD requires prevention of these adverse effects. Treatments to increase bone mineral density include (...) bisphosphonates and vitamin D and calcium supplements, and in adolescents with pubertal delay, testosterone. Bone health management is an important part of lifelong care for patients with DMD. OBJECTIVES: To assess the effects of interventions to prevent or treat osteoporosis in children and adults with DMD taking long-term corticosteroids; to assess the effects of these interventions on the frequency of vertebral fragility fractures and long-bone fractures, and on quality of life; and to assess adverse

Cochrane2017

97. Antenatal Corticosteroid Therapy for Fetal Maturation

Antenatal Corticosteroid Therapy for Fetal Maturation Antenatal Corticosteroid Therapy for Fetal Maturation - ACOG Menu ▼ Antenatal Corticosteroid Therapy for Fetal Maturation Page Navigation ▼ INTERIM UPDATE A correction was published in November 2017 for this title. Click to view the correction. Number 713, August 2017 (Replaces Committee Opinion No. 677, October 2016) Committee on Obstetric Practice This Committee Opinion was developed by the American College of Obstetricians (...) will be liable for any loss, damage, or claim with respect to any liabilities, including direct, special, indirect, or consequential damages, incurred in connection with this publication or reliance on the information presented. INTERIM UPDATE: This Committee Opinion is updated as highlighted to reflect a limited focused change to clarify that, among specific populations, antenatal corticosteroids should be administered when a woman is at risk of preterm delivery within 7 days. Antenatal Corticosteroid

American College of Obstetricians and Gynecologists2017

98. Guidelines for the Diagnosis and Management of Critical Illness-Related Corticosteroid Insufficiency (CIRCI) in Critically Ill Patients (Part I)

Guidelines for the Diagnosis and Management of Critical Illness-Related Corticosteroid Insufficiency (CIRCI) in Critically Ill Patients (Part I) Guidelines for the Diagnosis and Management of Critical Illn... : Critical Care Medicine You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page. You currently have no recent searches Enter your Email address: Wolters Kluwer Health may email you for journal alerts and information (...) to your colleague. Some error has occurred while processing your request. Please try after some time. Export to End Note Procite Reference Manager Save my selection doi: 10.1097/CCM.0000000000002737 Special Articles Objective: To update the 2008 consensus statements for the diagnosis and management of critical illness -related corticosteroid insufficiency (CIRCI) in adult and pediatric patients. Participants: A multispecialty task force of 16 international experts in critical care medicine

Society of Critical Care Medicine2017